期刊
WORLD JOURNAL OF CLINICAL ONCOLOGY
卷 12, 期 3, 页码 150-163出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.5306/wjco.v12.i3.150
关键词
Immunotherapy; Cancer; Malignancy; Adverse effects; Immune checkpoint inhibitor; Monoclonal antibody
类别
Immunotherapy is gaining popularity as a tumor-specific treatment and is becoming a key component in cancer management. However, with the increasing use of immunotherapeutic agents, physicians must familiarize themselves with and manage their adverse effects.
Immunotherapy is rapidly evolving secondary to the advent of newer immunotherapeutic agents and increasing approval of the current agents by the United States Food and Drug Administration to treat a wide spectrum of cancers. Immunotherapeutic agents have gained immense popularity due to their tumor-specific action. Immunotherapy is slowly transforming into a separate therapeutic entity, and the fifth pillar of management for cancers alongside surgery, radiotherapy, chemotherapy, and targeted therapy. However, like any therapeutic entity it has its own adverse effects. With the increasing use of immuno-therapeutic agents, it is vital for physicians to acquaint themselves with these adverse effects. The aim of this review is to investigate the common systemic adverse effects and toxicities associated with the use of different classes of immunotherapeutic agents. We provide an overview of potential adverse effects and toxicities associated with different classes of immunotherapeutic agents organized by organ systems, as well as an extensive discussion of the current recommendations for treatment and clinical trial data. As we continue to see increasing usage of these agents in clinical practice, it is vital for physicians to familiarize themselves with these effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据